Skip to main content

Table 1 Patient characteristics of the study population

From: The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

Characteristic

Percentage (%)/Median (range)

Age (years)

62.7

(32–85)

Baseline CA-125 level (U/mL)

725

(14–26,190)

Nadir CA-125 level (U/mL)

10

(6–35)

CA-125 level at relapse (U/mL)

124

(32–5528)

Histology

 High grade Serous

104

(73.2)

 High grade Endometrioid

26

(18.3)

 Undifferentiated

9

(6.3)

Malignant mixed müllerian tumor

3

(2.1)

Surgical residual of initial CRS

 < 1 cm

88

(62.0)

 1–2 cm

5

(3.5)

 > 2 cm

28

(19.7)

 Unknown

21

(14.8)

FIGO stage

 I

10

(7.0)

 II

11

(7.7)

 III

95

(63.6)

 IV

20

(14.1)

 Unknown

6

(4.2)

NAC

92

(63.4)

SNAC

55

(38.7)

BRCA mutations

5

(22.7)

Avastin® at recurrence

44

(31.0)

  1. FIGO the International Federation of Gynecology and Obstetrics, NAC Neo-adjuvant chemotherapy, SNAC Secondary Neo-adjuvant chemotherapy